Drug Interactions in Kenyan HIV Patients
Author Information
Author(s): Kigen Gabriel, Kimaiyo Sylvester, Nyandiko Winstone, Faragher Brian, Sang Edwin, Jakait Beatrice, Owen Andrew, Back David, Gibbons Sara, Seden Kay, Khoo Saye H.
Primary Institution: Moi University School of Medicine, Eldoret, Kenya
Hypothesis
What is the prevalence of clinically significant drug-drug interactions involving antiretroviral drugs in a large cohort of HIV patients in Kenya?
Conclusion
One in three patients receiving antiretrovirals in Kenya were at risk of clinically significant drug-drug interactions.
Supporting Evidence
- 33.5% of patients were at risk for clinically significant drug-drug interactions.
- Major interactions often involved rifampicin and azoles.
- Patients with lower CD4 counts and advanced disease stages were more likely to have drug interactions.
- Only 11.6% of patients were on second-line antiretroviral regimens.
Takeaway
Many people taking HIV medicine in Kenya might have problems with other medicines they are taking, which could make their HIV treatment less effective.
Methodology
The study surveyed prescriptions dispensed in a large HIV clinic in Kenya, screening 1040 patients and including 996 eligible patients.
Potential Biases
Potential underestimation of drug interactions due to incomplete data on other medications and traditional remedies.
Limitations
The study did not monitor for adverse outcomes from drug interactions and lacked comprehensive data on all medications used by patients.
Participant Demographics
The cohort included 346 males and 650 females aged 21-68 years, with a mean age of 39 years.
Statistical Information
P-Value
0.006
Confidence Interval
95% CI for CD4 count change: 112–138
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website